

FORM PTO-1390 (Modified)  
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

**PF86PCTSEQ**

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

**09/831061**

INTERNATIONAL APPLICATION NO.

**PCT/FR99/02734**

INTERNATIONAL FILING DATE

**08 NOV 1999 (08.11.99)**

PRIORITY DATE CLAIMED

**06 NOV 1998 (06.11.98)**

TITLE OF INVENTION

**USE OF ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS  
ANTIGEN-PRESENTING CELLS**

APPLICANT(S) FOR DO/EO/US

**BONNEFOY, Jean-Yves; LECOANET, Sybille; AUBRY, Jean-Pierre; JEANNIN, Pascale; BAUSSANT, Thierry**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☒ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☒ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☒ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☒ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

**Items 13 to 20 below concern document(s) or information included:**

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☐ Other items or information:

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) <b>09/831061</b>		INTERNATIONAL APPLICATION NO. <b>PCT/FR99/02734</b>		ATTORNEY'S DOCKET NUMBER <b>PF86PCTSEQ</b>	
--	--	--	--	---	--

24. The following fees are submitted:

BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5)) :			CALCULATIONS PTO USE ONLY	
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....	\$1000.00			
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....	\$860.00			
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....	\$710.00			
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....	\$690.00			
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) .....	\$100.00			
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>			<b>\$860.00</b>	
Surcharge of \$130.00 for furnishing the oath or declaration later than _____ months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30			<b>\$0.00</b>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	24 - 20 =	4	x \$18.00	<b>\$72.00</b>
Independent claims	3 - 3 =	0	x \$80.00	<b>\$0.00</b>
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				<b>\$0.00</b>
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$932.00</b>
<input type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				<b>\$0.00</b>
<b>SUBTOTAL =</b>				<b>\$932.00</b>
Processing fee of \$130.00 for furnishing the English translation later than _____ months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30			+	<b>\$0.00</b>
<b>TOTAL NATIONAL FEE =</b>				<b>\$932.00</b>
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				<b>\$0.00</b>
<b>TOTAL FEES ENCLOSED =</b>				<b>\$932.00</b>
			Amount to be:	\$
			refunded	\$
			charged	\$

a. ☒ A check in the amount of **\$932.00** to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **8-3220**. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING: Information on this form may become public. Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

<b>G. Patrick Sage</b> <b>THE FIRM OF HUESCHEN AND SAGE</b> <b>500 Columbia Plaza</b> <b>350 East Michigan Ave.</b> <b>Kalamazoo, MI 49007</b>	 SIGNATURE  <b>G. PATRICK SAGE</b> NAME  <b>37,710</b> REGISTRATION NUMBER  <b>May 4, 2001</b> DATE
--	---

\* \* \* \* \*

Applicant : Jean-Yves BONNEOY, Sybille LECOANET, Jean-Pierre  
AUBRY, Pascale JEANNIN, and Thierry BAUSSANT

Filed : May 4, 2001

Title : USE OF ENTEROBACTERIUM PROTEIN OmpA FOR  
SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING  
CELLS

\* \* \* \* \*

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

A soon as a Serial Number and Filing Date have been accorded the above-  
identified national phase application, kindly amend as follows:

IN THE CLAIMS: Kindly cancel all of the claims, 1 through 24, and replace by  
Claims 25 through 48 as provided herewith.

IN THE ABSTRACT: Herewith please find an Abstract of the Disclosure in U.S.  
format.

REMARKS

The present application is a national phase filing of PCT/FR99/02734.

Applicants have cancelled all of the originally-filed Claims, 1 through 24. New  
Claims, 25 through 48, have been added to better encompass the full scope and  
breadth of the invention notwithstanding Applicants belief that the Claims would

have been allowable as originally filed. Accordingly, Applicants assert that no Claims have been narrowed within the meaning of Festo.

A U.S. format Abstract is provided.

Entry of the new Claims and Abstract and early and favorable action on the merits of this application are respectfully solicited.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

By: G. Patrick Sage  
G. PATRICK SAGE

Dated: May 3, 2001  
Customer No.: 25,666  
500 Columbia Plaza  
350 East Michigan Ave.  
Kalamazoo, MI 49007  
(616) 382-0030

Enclosure: Postal Card Receipt  
Claims 25 through 48  
Abstract of the Disclosure

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847

66 1000

CLAIMS

25. A process of using an enterobacterium OmpA protein, or a fragment thereof, for preparing a composition intended for specific targeting of a biologically active substance, which is associated with it, to antigen-presenting cells, wherein said enterobacterium OmpA protein, or a fragment thereof, is internalized into the antigen-presenting cells.

26. The process of claim 25, wherein said enterobacterium OmpA protein, or a fragment thereof, binds specifically to antigen-presenting cells.

27. The process of claim 25, wherein said antigen-presenting cells are chosen from dendritic cells, monocytes and B lymphocytes.

28. The process of claim 27, wherein said antigen-presenting cells are dendritic cells.

29. The process of claim 25, wherein said enterobacterium OmpA protein, or a fragment thereof, is obtained from a culture of said enterobacterium, using an extraction process.

30. The process of claim 25, wherein said enterobacterium OmpA protein, or a fragment thereof, is obtained by a recombinant process.

31. The process of claim 25, wherein said enterobacterium is *Klebsiella pneumoniae*.

32. The process of claim 31, wherein the amino acid sequence of said OmpA protein, or a fragment thereof, comprises:

- a) the amino acid sequence having sequence SEQ ID No 2;
- b) the amino acid sequence of a sequence having at least 80% homology with the sequence SEQ ID No 2; or
- c) the amino acid sequence of a fragment, of at least 5 amino acids, of a sequence as defined in a) or b).

0931051-083404

33. The process of claim 25, wherein said biologically active substance is chosen from peptides, lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids and chemical substances.

34. The process of claim 33, wherein said biologically active substance is coupled by covalent attachment with said OmpA protein, or a fragment thereof.

35. The process of claim 34, wherein the coupling by covalent attachment is chemical coupling.

36. The process of claim 35, wherein one or more attachment elements are introduced into said OmpA protein, or a fragment thereof, and/or into said biologically active substance, in order to facilitate the chemical coupling.

37. The process of claim 36, wherein said attachment element introduced is an amino acid.

38. The process of claim 34, wherein said biologically active substance coupled by covalent attachment with said OmpA protein, or a fragment thereof, is a recombinant chimeric protein resulting from the expression of a nucleic acid construct encoding said biologically active substance and said OmpA protein, or a fragment thereof.

39. The process of claim 38, wherein said biologically active substance is an antigen or a hapten.

40. A method for modifying the immune response to an antigen or a hapten with a composition intended for specific targeting of a biologically active substance, which is associated with it, to antigen-presenting cells, wherein an enterobacterium OmpA protein, or a fragment thereof, is internalized into the antigen-presenting cells.

41. The method of claim 40 for improving the immune response to an antigen or a hapten.

42. The method of claim 40 for preventing or treating a disease.

05831061 08231071

43. The method of claim 42, for preventing or treating a disease with an active substance, the effectiveness of which is modified by and/or linked to the internalization thereof by dendritic cells.

44. The method of claim 43, for preventing or treating cancers, preferably cancers associated with a tumor antigen, autoimmune diseases, allergies, graft rejections, cardiovascular diseases, diseases of the central nervous system, inflammatory diseases, infectious diseases or diseases linked to an immunodeficiency.

45. The method of claim 44, for preventing or treating an infectious disease or a cancer associated with a tumor antigen.

46. A pharmaceutical composition effective in the method of claim 42 which comprises an adjuvant of immunity.

47. The pharmaceutical composition of claim 46 which is vehicled in a form which makes it possible to improve the stability and/or immunogenicity thereof.

48. The pharmaceutical composition of claim 46 which is vehicled in the form of a liposome, of a viral vector, or of a transformed host cell capable of expressing a recombinant chimeric protein resulting from the expression of a nucleic acid construct encoding said biologically active substance and said OmpA protein, or a fragment thereof.

09331061 033101



4/PR TS

097/831061  
JC18 Rec'd PCT/PTO 04 MAY 2001

WO 00/27432

PCT/FR99/02734

USE OF AN ENTEROBACTERIUM OmpA PROTEIN FOR SPECIFIC  
TARGETING TO ANTIGEN-PRESENTING CELLS

5           The invention relates to the use of an  
enterobacterium OmpA protein, preferably the *Klebsiella*  
*pneumoniae* P40 protein, for specific targeting of a  
biologically active substance which is associated with  
it to antigen-presenting cells, in particular human  
10 dendritic cells. The invention also relates to the use  
of the OmpA protein for preparing a pharmaceutical  
composition intended for the prevention and/or  
treatment of diseases, in particular cancers associated  
with a tumor antigen, autoimmune diseases or infectious  
15 diseases.

Vaccination is an effective means of preventing  
or attenuating viral or bacterial infections. The  
success of vaccination campaigns in this domain has  
made it possible to extend the vaccine concept to other  
20 domains, such as that of cancer and of autoimmune  
diseases. With regard, for example, to certain forms of  
cancer, the ineffectiveness of conventional therapies  
and/or their side effects, such as chemotherapy or  
radiotherapy, has prompted the search for alternative  
25 therapy. Thus, specific tumor antigens expressed at the  
surface of tumor cells can be used as a target in  
immunotherapy for the elimination of these cells. One  
of the major problems commonly encountered in preparing  
these vaccines is that the vaccine antigens, when they  
30 are administered alone to the host, are not immunogenic  
enough to induce an immune response which is  
sufficiently effective to confer the desired  
protection. These antigens are thus often covalently  
coupled to a carrier molecule such as, for example, an  
35 epitope of the diphtheria toxin, the tetanus anatoxin  
(TT), a surface antigen of the hepatitis B virus, the  
VP1 antigen of the poliomyelitis virus or any other  
toxin, or viral or bacterial antigen, such as antigenic  
proteins derived from the enterobacterium external

097/831061

membrane, which have the property of potentiating the immune response (humoral or cellular) of the antigen which is associated with it, for instance the OmpA protein named P40 derived from *Klebsiella pneumoniae* (described in international patent applications WO 95/27787 and WO 96/14415). However, in most cases, another component has proved to be necessary in order to increase the effectiveness of the vaccine and, currently, the only adjuvant authorized in humans is alum.

Through immunology, it has recently been discovered that dendritic cells (DCs) play a major role in the immune system. These cells, derived from bone marrow stem cells, are professional antigen-presenting cells involved in the antigen-specific primary immune response (Peters J. et al., 1996). They ingest or internalize antigens and present the fragments of these antigens to naïve T cells. This ingestion induces, at the surface of the dendritic cells, the expression of costimulation molecules such as CD80 and CD86. These molecules allow close interaction with T cells (Girolomoni G. and Ricciardi-Castagnoli P., 1997, *Immunol. Today*, 18, 102-104). Dendritic cells are distributed diffusely in tissues. They are found in the skin and lymphoid organs (Hinrich J. et al., 1996, *Immunol. Today*, 17, 273-277).

Due to their effectiveness in presenting antigens and in stimulating the immune system, dendritic cells have been used to generate antiviral (Ludewig B. et al., 1998, *J. Virol.*, 72, 3812-3818; Brossard P. et al., 1997, *J. Immunol.*, 158, 3270-3276) or anticancer (Nestle F.O. et al., 1998, *Nat. Med.*, 4, 328-332) cytotoxic CTL responses. Approaches have consisted in loading dendritic cells *ex vivo* with the antigen of interest (peptides or cell lysate) and reimplanting these cells in the patient. Other approaches consist in transfecting dendritic cells *ex vivo* with the gene encoding the antigen of interest and in reinjecting these transfected cells (Gilboa E. et

al., 1998, Cancer Immunol. Immunother., 46, 82-87). These approaches have been used successfully in mice and recently in humans (Hsu F.J. et al., 1996, Nat. Med., 2, 52-58). Dendritic cells loaded with antigens  
5 present the peptides via class I or II molecules, and induce the activation of CD4 or CD8+ T lymphocytes. Consequently, the possibility of directing the antigens chosen, such as proteins or polysaccharides, or viral vectors capable of transferring genes encoding these  
10 antigens, toward dendritic cells would make it possible to improve the effectiveness of immune system stimulation. In addition, specific targeting of antigen-presenting cells (APCs), in particular dendritic cells, would make it possible to avoid the  
15 steps of removal, of purification and of ex vivo treatment of autologous or heterologous APCs with the tumor antigens or the viral vectors, and the reimplantation of the treated APCs.

In order to specifically target dendritic cells  
20 with active substances of interest, such as proteins or viral vectors capable of transferring genes encoding these proteins of interest, many studies have consisted in identifying molecules which would bind preferentially to the dendritic cells, or receptors  
25 which would be expressed specifically on the dendritic cells. A receptor DEC 205, involved in the treatment of the antigen, has been identified on murine (Jiang W. et al., 1995, Nature, 375, 151-155) and human (Kato M. et al., 1998, Immunogenetics, 47, 442-450) dendritic  
30 cells. The analysis of the structure of this receptor reveals carbohydrate-recognition domains which are thought to be involved in the capture, internalization and/or presentation of antigens carrying carbohydrate residues. However, the authors give no information  
35 concerning the ligands which can be bound by this receptor. On the other hand, the authors mention that the carbohydrate-recognition domains of the receptor DEC-205 which are thought to be involved in the capture, internalization and/or presentation of

antigens (cysteine-rich domains) are also present in more than 50 proteins, including some cell receptors.

Thus, there exists, today, a need for a compound which is capable of specifically targeting an antigen-presenting cell (APC), in particular a dendritic cell, and which is also capable of being internalized by said cell. Such a compound capable of binding specifically to these cells, and then of being internalized, would have the advantage of being able to be used as a compound for the transport and targeting of a biologically active substance, the effectiveness of which is modified by and/or linked to the binding and/or the internalization of this substance by these cells. In addition, it would be advantageous if this compound being sought could be easily associated with the active substance by chemical coupling or by coupling resulting from genetic fusion, or if it could be expressed at the surface of a host cell or at the surface of a viral particle for the transfer of a gene of interest into these APCs.

The authors of the present invention have demonstrated, surprisingly, that an enterobacterium external membrane protein of OmpA type, in particular the *Klebsiella pneumoniae* P40 protein, is capable not only of binding specifically to an APC, but also capable of being internalized by said APC, in particular by a dendritic cell.

Thus, the present invention relates to the use of an enterobacterium OmpA protein, or of a fragment thereof, for specific targeting of a biologically active substance which is associated with it to antigen-presenting cells.

In the present invention, the expression "antigen-presenting cells" will be intended to refer to professional APCs which form an integral part of the immune system, such as dendritic cells, macrophages, B lymphocytes or monocytes.

In the present invention, the term "protein" will also be intended to refer to peptides or

09831061.083101

polypeptides, and the term "OmpA" (for "Outer Membrane Protein") will be intended to refer to external membrane proteins of type A.

5 The expression "fragment of an OmpA protein" is intended to refer to any fragment of amino acid sequence included in the amino acid sequence of the OmpA protein capable of binding specifically to APCs, in particular dendritic cells, and comprising at least 5 amino acids, preferably 10 amino acids, or more  
10 preferably 15 amino acids, said fragments also being capable of being internalized into said APCs.

15 The expression "biologically active substance" is intended to refer to any compound which is capable of exercising therapeutic activity and the activity of which can be modified via APCs. Mention may be made, as an example of such biologically active substances, but without being limited thereto, of immunogenic compounds such as antigens or haptens which are protein, poly- or oligosaccharide, glycoprotein or lipoprotein in nature,  
20 or in general of organic origin, these immunogenic compounds possibly being carried by complex structures such as bacteria or viral particles.

25 The expression "biologically active substance" is also intended to refer to any compound capable of modifying the functional activity of APCs, in particular the growth, differentiation or system of expression thereof. Mention may be made, as an example of such biologically active substances, but without being limited thereto, of cellular growth factors  
30 including cytokines (IL-4, IL-3, GM-CSF, TNF- $\alpha$ ), and nucleic acids which encode homologous or heterologous proteins of interest and which are capable of being expressed by APCs.

35 A subject of the invention is also the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, characterized in that said enterobacterium OmpA protein, or a fragment thereof, binds specifically to antigen-presenting cells, and in that said enterobacterium OmpA protein,

or a fragment thereof, is internalized into the antigen-presenting cells.

Preferably, the invention comprises the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, characterized in that said antigen-presenting cells are chosen from dendritic cells, monocytes and B lymphocytes, more preferably dendritic cells.

In a particular embodiment, the invention comprises the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, characterized in that said enterobacterium OmpA protein, or a fragment thereof, is obtained from a culture of said enterobacterium, using an extraction process.

Processes for extraction of bacterial membrane proteins are known to those skilled in the art and will not be developed in the present description. Mention may be made, for example, but without being limited thereto, of the extraction process described by Hauew J.H. et al. (Eur. J. Biochem, 255, 446-454, 1998).

In another preferred embodiment, the invention also comprises the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, characterized in that said enterobacterium OmpA protein, or a fragment thereof, is obtained by recombinant process.

Methods for preparing recombinant proteins are today well known to those skilled in the art and will not be developed in the present description; reference may, however, be made to the method described in the examples. Among the cells which can be used for producing these recombinant proteins, it is of course necessary to mention bacterial cells (Olins P.O. and Lee S.C., 1993, Recent advances in heterologous gene expression in E. coli. Curr. Op. Biotechnology 4:520-525), but also yeast cells (Buckholz R.G., 1993, Yeast Systems for the Expression of Heterologous Gene

09331061 033101

Products. Curr. Op. Biotechnology 4:538-542), as well as animal cells, in particular cultures of mammalian cells (Edwards C.P. and Aruffo A., 1993, Current applications of COS cell based transient expression systems. Curr. Op. Biotechnology 4:558-563), and also insect cells in which it is possible to use processes implementing baculoviruses for example (Luckow V.A., 1993, Baculovirus systems for the expression of human gene products. Curr. Op. Biotechnology 4:564-572).

10 Most preferably, the use according to the invention is characterized in that said enterobacterium is *Klebsiella pneumoniae*.

In particular, the invention relates to the use according to the invention, characterized in that the amino acid sequence of said *Klebsiella pneumoniae* OmpA protein, or a fragment thereof, comprises:

- 15 a) the amino acid sequence having the sequence SEQ ID No 2;
- 20 b) the amino acid sequence of a sequence having at least 80%, preferably at least 85%, 90% or 95%, homology with the sequence SEQ ID No 2; or
- c) the amino acid sequence of a fragment, of at least 5 amino acids, of a sequence as defined in a) or b).

The expression "sequence having at least 80%, preferably at least 85%, 90% or 95%, homology with the reference sequence SEQ ID No 2" is intended to refer to an amino acid sequence having a degree of identity, after optimal alignment, of at least 80%, 85%, 90% or 95%, respectively, with the reference sequence SEQ ID No 2, said homologous sequence, or a said fragment thereof of at least 5 amino acids as defined above in c), being characterized in that it binds specifically to antigen-presenting cells and, where appropriate, in that it is internalized into the antigen-presenting cells.

For the purpose of the invention, the expression "percentage of identity" between two nucleic acid or amino acid sequences is intended to refer to a percentage of nucleotides or of amino acid residues

09871061 "033101

which are identical between the two sequences to be compared, obtained after the best alignment, this percentage being purely statistical and the differences between the two sequences being distributed randomly and throughout their length. The best alignment or optimal alignment is the alignment for which the percentage of identity between the two sequences to be compared, as calculated hereinafter, is highest. Sequence comparisons between two nucleic acid or amino acid sequences are conventionally carried out by comparing these sequences after having aligned them optimally, said comparison being carried out by segment or by "window of comparison", so as to identify and compare local regions of sequence similarity. The optimal alignment of the sequences for comparison can be produced, other than manually, by means of the local homology algorithm of Smith and Waterman (1981) [Ad. App. Math. 2:482], by means of the local homology algorithm of Neddleman and Wunsch (1970) [J. Mol. Biol. 48:443], by means of the similarity search method of Pearson and Lipman (1988) [Proc. Natl. Acad. Sci. USA 85:2444], by means of computer software using these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI, or BLASTN or BLASTX, Altschul et al., J. Mol. Biol. 215, 403, 1990).

The percentage of identity between two nucleic acid or amino acid sequences is determined by comparing these two optimally aligned sequences by window of comparison in which the region of the nucleic acid or amino acid sequence to be compared can comprise additions or deletions with respect to the reference sequence for optimal alignment between these two sequences. The percentage of identity is calculated by determining the number of identical positions for which the nucleotide or amino acid residue is identical between the two sequences, dividing this number of identical positions by the total number of positions in the window of comparison, and multiplying the result

09031061 083101



The invention also comprises the use according to the invention, characterized in that said biologically active substance is chosen from proteins or peptides, lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids and chemical substances.

In a particular embodiment, the use according to the invention is characterized in that one or more attachment elements is (are) introduced into said OmpA protein, or a fragment thereof, and/or into said  
20 biologically active substance, in order to facilitate the chemical coupling; preferably said attachment element introduced is an amino acid.

According to the invention, it is possible to introduce one or more attachment elements, in particular amino acids, in order to facilitate the coupling reactions between the OmpA protein, or a fragment thereof, and the biologically active substance, such as an antigen or a hapten. The covalent coupling between the OmpA protein, or a fragment thereof, and the biologically active substance, such as an antigen or a hapten, according to the invention can be carried out at the N- or C-terminal end of the OmpA protein, or a fragment thereof. The bifunctional reagents which allow this coupling will be determined as a function of the end of the OmpA protein, or a fragment thereof, chosen to perform the coupling, and on the nature of the biologically active substance to be coupled.

In another particular embodiment, the use according to the invention is characterized in that said biologically active substance coupled by covalent attachment with said OmpA protein, or a fragment thereof, is a recombinant chimeric protein resulting from the expression of a nucleic acid construct encoding said biologically active substance and said OmpA protein, or a fragment thereof.

The conjugates derived from coupling to said OmpA protein, or a fragment thereof, can be prepared by genetic recombination. The chimeric or hybrid protein (conjugate) can be produced using recombinant DNA techniques, by insertion into or addition to the DNA sequence encoding said OmpA protein, or a fragment thereof, of a sequence encoding said biologically active substance which is protein in nature.

The processes for synthesizing the hybrid molecules encompass the methods used in genetic engineering for constructing hybrid polynucleotides encoding the desired polypeptide sequences. Reference may, for example, be advantageously made to the technique for obtaining genes encoding fusion proteins, described by D.V. Goeddel (Gene expression technology, Methods in Enzymology, vol. 185, 3-187, 1990).

The invention relates most particularly to the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, characterized in that said biologically active substance is an antigen or a hapten.

In another aspect, the invention relates to the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, for modifying the immune response against an antigen or a hapten, preferably for improving the immune response against an antigen or a hapten.

The invention also comprises the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, for preparing a pharmaceutical composition intended to prevent or to

treat a disease with an active substance, the effectiveness of which is modified by and/or linked to the internalization thereof by antigen-presenting cells, preferably by dendritic cells.

5 Preferably, the use according to the invention is related to the preparation of a pharmaceutical composition intended to prevent or to treat cancers, preferably cancers associated with a tumor antigen, autoimmune diseases, allergies, graft rejections,  
10 cardiovascular diseases, diseases of the central nervous system, inflammatory diseases, infectious diseases or diseases linked to an immunodeficiency.

A subject of the invention is in particular the use of an enterobacterium OmpA protein, or of a  
15 fragment thereof, according to the invention, for preparing a pharmaceutical vaccine composition intended to prevent or to treat an infectious disease or a cancer associated with a tumor antigen.

The invention also comprises the use according  
20 to the invention, characterized in that said pharmaceutical composition also comprises an adjuvant which promotes the immune response, such as alum.

The invention also comprises the use according to the invention, characterized in that said  
25 pharmaceutical composition is vehicled in a form which makes it possible to improve the stability and/or the immunogenicity thereof, in particular in the form of a liposome, of a viral vector or of a transformed host cell capable of expressing a recombinant chimeric  
30 protein resulting from the expression of a nucleic acid construct encoding said biologically active substance and said OmpA protein, or a fragment thereof.

The legends of the figures and examples which follow are intended to illustrate the invention without  
35 in any way limiting the scope thereof.

Legends of the figures:

Figure 1: Binding of rP40-Alexa to various cell types. After incubation of rP40-Alexa on various cell types, the specific binding of rP40-Alexa (bold line) is

0933061 03194

measured by flow cytometry. The binding of a nonrelevant protein (glycophorin) is represented with a fine line.

5 Figure 2: Influence of the concentration of rP40 on the binding to dendritic cells.

Figure 3: Inhibition of the binding of rP40-Alexa to dendritic cells, with unlabeled rP40.

10 After incubation of dendritic cells with various concentrations of unlabeled rP40, rP40-Alexa is added. The binding of rP40-Alexa is quantified by flow cytometry.

Figure 4: Evaluation of the binding of various labeled proteins to dendritic cells.

15 P40, TT (tetanus anatoxin) and BB (derived from the streptococcus G protein) carrier proteins labeled with Alexa are incubated with dendritic cells (thick line). A nonrelevant protein is used as a negative control (fine line). The binding is measured by flow cytometry.

20 Figure 5A and 5B: Internalization of rP40-Alexa into dendritic cells.

After incubation of dendritic cells with rP40-Alexa at 4°C (left-hand panel, figure 5A) or at 37°C (right-hand panel, figure 5B), the cells are observed by confocal microscopy (x 220 magnification).

25

#### **Example 1: Cloning of the rP40 gene**

30 The gene encoding the recombinant P40 protein, named rP40, was obtained by PCR amplification using the genomic DNA of *Klebsiella pneumoniae* IP I145 (Nguyen et al., Gene, 1998). The coding gene fragment of rP40 is inserted into various expression vectors, in particular a vector under the control of the Trp operon promoter. The amino acid sequence of the rP40 protein and the nucleotide sequence encoding the P40 protein are  
35 represented by the sequences SEQ ID No 2 and SEQ ID No 1, respectively, in the sequence listing hereinafter.

An *E. coli* K12 producer strain was transformed with an expression vector pvaLP40. The rP40 protein is

produced in the form of inclusion bodies with a significant yield (> 10%, g of proteins/g of dry biomass). This example is only an illustration of the expression of rP40, but it may be extended to other bacterial strains, and also to other expression vectors.

**Example 2:** Process for fermenting rP40 fusion proteins

An Erlenmeyer containing 250 ml of TSB (Tryptic Soy Broth, Difco) medium containing ampicillin (100 µg/ml, Sigma) and tetracycline (8 µg/ml, Sigma) is inoculated with the recombinant *E. coli* strain described above. The incubation is carried out overnight at 37°C, and then 200 ml of this culture is used to seed 2 liters of culture medium in a fermenter (Biolafitte, France). In a quite conventional way, the culture medium can be composed of chemical agents, supplemented with vitamins and/or yeast extracts, known to have a growth at high density of bacterial cells.

The parameters controlled during the fermentation are: the pH, the stirring, the temperature, the level of oxygenation and the supply of combined sources (glycerol or glucose). In general, the pH is regulated at 7.0 and the temperature is fixed at 37°C. The growth is controlled by supplying glycerol (87%) at a constant flow rate (12 ml/h) so as to maintain the dissolved oxygen tension signal at 30%. When the turbidity of the culture (measured at 580 nm) reaches the value of 80 (after approximately 24 hours of culturing), the protein production is triggered by adding indole acrylic acid (IAA) at the final concentration of 25 mg/l. Approximately 4 hours after induction, the cells are harvested by centrifugation. The amount of wet biomass obtained is approximately 200 g.

**Example 3:** Process for extracting and for purifying the rP40 protein

### Extraction of rP40

After centrifugation of the culture broth (4000 rpm, 10 min, 4°C), the cells are resuspended in a 25 mM Tris-HCl buffer, pH 8.5. The insoluble substances or inclusion bodies are obtained after treatment with lysozyme (0.5 g/liter, 1 hour at room temperature / gentle stirring). The inclusion body pellet obtained by centrifugation (50 min at 10 000 g at 4°C) is taken up in a 25 mM Tris-HCl buffer at pH 8.5, containing 5 mM MgCl<sub>2</sub>, and then centrifuged (15 min at 10 000 g).

The inclusion bodies are solubilized at 37°C for 2 hours in a 25 mM Tris-HCl buffer, pH 8.5, containing 7 M urea (denaturing agent) and 10 mM dithiothreitol (reduction of disulfide bridges). Centrifugation (15 min at 10 000 g) makes it possible to eliminate the insoluble particles.

Thirteen volumes of 25 mM Tris-HCl buffer, pH 8.5, containing NaCl (8.76 g/l) and Zwittergent 3-14 (0.1%, w/v) are then used to resuspend. The solution is left overnight at room temperature with gentle stirring, in contact with the air (promotes the renaturation of the protein by dilution and reoxidation of the disulfide bridges).

### Purification of the rP40 protein

Anion exchange chromatography step.

After a further centrifugation, the solution is dialyzed against a 25 mM Tris-HCl buffer, pH 8.5, containing 0.1% Zwittergent 3-14 (100 X volumes of buffer) overnight at 4°C.

The dialysate is loaded onto a column containing a support of strong anion exchange type (Biorad Macro Prep High Q gel), equilibrated in the buffer described above, at a linear flow rate of 15 cm/h. The proteins are detected at 280 nm. The rP40 protein is eluted, with a linear flow rate of 60 cm/h, for a concentration of NaCl of 0.2 M in the 25 mM Tris-HCl, pH 8.5, 0.1% Zwittergent 3-14 buffer.

Cation exchange chromatography step

The fractions containing the rP40 protein are pooled and concentrated by ultrafiltration with the aid of an Amicon stirring cell system used with a Diaflo  
5 membrane of YM10 type (cut-off threshold 10 kDa), for volumes of about 100 ml, or with the aid of a millipore Minitan tangential-flow filtration system used with membrane plates having a cut-off threshold of 10 kDa, for larger volumes. The fraction thus concentrated is  
10 dialyzed overnight at 4°C against a 20 mM citrate buffer, pH 3.0, containing 0.1% of Zwittergent 3-14.

The dialysate is loaded onto a column containing a support of strong cation exchange type (Biorad Macro Prep High S gel), equilibrated in the  
15 20 mM citrate buffer, pH 3.0, containing 0.1% of Zwittergent 3-14. The rP40 protein is eluted (rate 61 cm/h) for a concentration of NaCl of 0.7 M. The electrophoretic profiles show a degree of purity of about 95%. The condition of the protein is monitored by  
20 SDS-PAGE. The P40 protein extracted from the *Klebsiella pneumoniae* membrane has a characteristic electrophoretic behavior (migration) according to its denatured or native form. The native form ( $\beta$ -sheet structure) in fact has a lower molecular mass than the  
25 form denatured ( $\alpha$ -helix structure) under the action of a denaturing agent, such as urea or guanidine hydrochloride, or with heating at 100°C in the presence of SDS. The rP40 protein is not correctly renatured at the end of renaturation, whether this renaturation is  
30 carried out in the presence or absence of 0.1% (w/v) Zwittergent 3-14. On the other hand, total renaturation is obtained after dialysis against a 25 mM Tris/HCl buffer, pH 8.5, containing 0.1% (w/v) of Zwittergent 3-14. However, it should be noted that this renaturation  
35 is obtained only when the dilution step and the treatment at room temperature are, themselves, carried out in the presence of Zwittergent 3-14 (negative results in the absence of detergent).

0931031.08301

**Example 4:** Specific binding of rP40 to antigen-presenting cells (APCs). Methodology

Purification of human T lymphocytes

Mononucleated cells (MNCs) are isolated from the peripheral blood of healthy volunteers, by centrifugation (1800 rpm, 20 min, room temperature), on a Ficoll gradient. After centrifugation, the MNCs, located at the ficoll/plasma interface, are harvested and washed twice with complete culture medium (CM) (RPMI 1640 + 10% FCS + L-glutamine + antibiotic). The T lymphocytes are then isolated by the rosetting technique, which uses their capacity to bind to sheep red blood cells (SRBCs). Briefly, the MNCs are incubated with SRBCs for 1 hour at 4°C. After centrifugation on a ficoll gradient, the B lymphocytes and monocytes are located at the interface, whereas the T lymphocytes bound to the SRBCs are in the cell pellet. After recovery of the cell pellet and lysis of the SRBCs with a hypotonic saline solution, the purity of the T lymphocytes is assessed by flow cytometry with an anti-CD3 antibody, and is greater than 95%.

Purification of the human monocytes

The monocytes are purified from the MNCs by positive selection using MACS (Magnetic Activated Cell Sorter) technology. The MNCs are labeled with an anti-CD14 antibody coupled to magnetic particles, and then passed over a magnetized column. The monocytes to which the antibody-colloid complexes are bound remain in the column, whereas the cells which have not bound the antibody are eluted with successive washes. Next, the monocytes are detached by performing washes in the absence of magnet. The purity of the fraction collected is greater than 98%.

Generation of human dendritic cells (DCs) from monocytes

The purified monocytes are cultured at the concentration of 106/ml in CM for 6 to 7 days, in the presence of IL 4 (20 ng/ml) and of CMCSF (20 ng/ml). The DCs generated at this stage are immature DCs which



express CD1a and no, or relatively little, CD83. Their phenotype is verified using the flow cytometry technique.

#### Purification of human B lymphocytes from tonsils

5           The tonsils are ground, and the cells harvested are loaded onto a ficoll gradient. The MNCs recovered at the interface are washed and then incubated with SRBCs. After ficoll, the B lymphocytes are located at the interface, whereas the T lymphocytes bound to the  
10 SRBCs are in the cell pellet. The B lymphocytes are then washed. Their purity, verified by flow cytometry, is greater than 96%.

#### Culturing of cell lines

15           The RPMI 8866, DAUDI, HL60 and Jurkat cell lines are cultured in CM.

#### Coupling of rP40 to the Alexa488 fluorochrome

20           The concentration of the rP40 protein is adjusted to 2 mg/ml in PBS. 50 µl of 1 M sodium bicarbonate are added to 500 µl of the protein. The solution is then transferred into a reaction tube containing the Alexa488 dye and the coupling takes place at room temperature. After 1 h, the coupling reaction is stopped by adding 15 µl of hydroxylamine. The labeled protein is separated from the free dye by  
25 column purification.

          The amount of rP40 labeled with Alexa488 is then estimated by colorimetric assay.

-       Study of the binding of p40-Alexa488 to the various cells, by flow cytometry.

30           For each labeling, 200 000 cells are washed with FACS buffer (PBS + 1% BSA + 0.01% sodium azide) and resuspended, in a cone-bottomed 96-well plate, in 50 µl of FACS buffer. The P40-Alexa488 protein or the control protein (glycophorin-Alexa488) are then added  
35 at  $10^{-6}$ M for approximately 1 h at 4°C. After incubation, the cells are then washed 3 times with FACS buffer, and then resuspended in 200 µl of this same buffer and analyzed by flow cytometry.

Result

The rP40 protein binds selectively to human APCs such as:

- the monocytes derived from human blood,
- 5 - the dendritic cells generated from the peripheral blood monocytes,
- the B lymphocytes derived from tonsils, the B-lymphocyte lines: DAUDI and RPMI 8866 (cf. fig. 1) and the B lymphocytes derived from peripheral blood (result not shown).

10 No binding is observed to cells which do not have the capacity to present antigens, such as nonactivated peripheral blood T lymphocytes, the nonactivated Jurkat T-lymphocyte line and the  
15 nonactivated HL60 monocyte line.

**Example 5:** The binding of rP40 to the DCs is specific

1) The binding of rP40 to the DCs is dose-dependent.

20 Method

200 000 DCs are washed with FACS buffer and incubated in 50 µl of buffer in the presence of various concentrations of rP40 (from  $10^{-10}$  to  $5 \times 10^{-6}$  M) for approximately 1 hour at 4°C. After incubation, the  
25 cells are washed 3 times with FACS buffer, and then resuspended in 50 µl of this same buffer containing 5 µg/ml of an anti-P40 rabbit polyclonal antibody or of a control rabbit IgG antibody. After incubation for 20 minutes, the cells are rewashed and incubated in 100 µl  
30 of FACS buffer containing a fluoresceine-labeled anti-rabbit IgG goat polyclonal antibody (diluted to 1:200). After incubation for 20 minutes, the cells are washed, taken up in FACS buffer and analyzed by flow cytometry.

Result

35 The binding of rP40 to the DC is significant from  $10^{-7}$  M ( $p < 0.001$ ) and at a maximum at  $2 \times 10^{-6}$  M (cf. fig. 2).

2) Unlabeled rP40 protein decreases the binding of rP40 Alexa488 to the DCs.

0931061.03101

### Method

In order to demonstrate the specificity of the binding of P40, competition is carried out between rP40-Alexa488 and unlabeled rP40. The DCs were incubated for 10 minutes with  $5 \times 10^{-8}$  to  $2 \times 10^{-6}$  M of unlabeled rP40, and then P40-Alexa488 (used at  $2 \times 10^{-6}$  M) was added. After incubation for 20 minutes at 4°C, the cells were analyzed by flow cytometry as described previously.

### Result

The unlabeled rP40 protein inhibits, in a dose-dependent manner, the binding of  $2 \times 10^{-6}$  M of P40 Alexa488 (at more than 60% when it is used at  $2 \times 10^{-6}$  M) (cf. fig. 3).

**Example 6:** Among the TT, BB and rP40 carrier proteins, only the rP40 protein binds to the DCs.

### Method

The tetanus anatoxin (TT) and BB (originating from the streptococcus G protein having affinity for human albumin) carrier proteins, and also the rP40 protein and the glycophorin A control protein were labeled with Alexa488 as described above. The binding of these molecules to the DCs was evaluated by flow cytometry as previously described. Briefly, 200 000 DCs are washed with FACS buffer and incubated in 50 µl of buffer in the presence of  $10^{-6}$  M of each of the Alexa488-labeled proteins for approximately 1 hour at 4°C. After incubation, the cells are washed 3 times with FACS buffer, and then resuspended in 200 µl of this same buffer and analyzed by flow cytometry.

### Result

At the concentration of  $10^{-6}$  M, only rP40 binds to the dendritic cells. No binding of TT, BB and glycophorin is detected (cf. fig. 4).

**Example 7: rP40 is internalized by the DCs**

Method

200 000 DCs are washed with PBS-1% BSA buffer and resuspended, in a cone-bottomed 96-well plate, in 50 µl of PBS-BSA buffer (saline phosphate-bovine serum albumin buffer). The rP40-Alexa488 protein or the glycophorin-Alexa488 protein is then added at  $2 \times 10^{-6}$  M. Internalization kinetics are produced by incubating the cells with the Alexa-labeled proteins at 37°C for 15 minutes to 2 hours. A negative control for internalization is carried out under the same conditions, changing the following parameters: addition of 0.01% sodium azide to the PBS-BSA buffer and incubation of these cells with the Alexa-labeled proteins, at 4°C.

After incubation, the cells are then washed 3 times with PBS-BSA buffer, resuspended in 100 µl of this same buffer and then cytospun onto microscope slides. The slides are then analyzed by confocal microscopy.

Result

The observation of the cells incubated at 37°C with rP40-Alexa shows intracytoplasmic labeling which is detectable from 30 minutes and still observed after incubation for 2 h: a representative result, obtained after incubation for 1 h at 37°C is shown in figure 5B. Labeling of the membrane, but not intracytoplasmic labeling, is observed when the cells are incubated at 4°C with rP40 (cf. fig. 5A), whereas no labeling is observed in the presence of glycophorin-Alexa (after incubation at 4°C as at 37°C). The example of Alexa, a chemical molecule, demonstrates that any chemical molecule coupled to P40 can thus be delivered to antigen-presenting cells, including dendritic cells.

09-25-2000

FR 009902734

- 21 -

CLAIMS

1. The use of an enterobacterium OmpA protein, or  
5 of a fragment thereof, for preparing a pharmaceutical  
composition intended for specific targeting of a  
biologically active substance which is associated with  
it to antigen-presenting cells, characterized in that  
said enterobacterium OmpA protein, or a fragment  
10 thereof, is internalized into the antigen-presenting  
cells.

2. The use as claimed in claim 1, characterized in  
that said enterobacterium OmpA protein, or a fragment  
thereof, binds specifically to antigen-presenting  
15 cells.

3. The use as claimed in either of claims 1 and 2,  
characterized in that said antigen-presenting cells are  
chosen from dendritic cells, monocytes and B  
lymphocytes.

4. The use as claimed in claim 3, characterized in  
that said antigen-presenting cells are dendritic cells.

5. The use as claimed in one of claims 1 to 4,  
characterized in that said enterobacterium OmpA  
protein, or a fragment thereof, is obtained from a  
25 culture of said enterobacterium, using an extraction  
process.

6. The use as claimed in one of claims 1 to 4,  
characterized in that said enterobacterium OmpA  
protein, or a fragment thereof, is obtained by  
30 recombinant process.

7. The use as claimed in one of claims 1 to 6,  
characterized in that said enterobacterium is  
*Klebsiella pneumoniae*.

8. The use as claimed in claim 7, characterized in  
35 that the amino acid sequence of said OmpA protein, or a  
fragment thereof, comprises:

- a) the amino acid sequence having sequence  
SEQ ID No 2;

- b) the amino acid sequence of a sequence having at least 80% homology with the sequence SEQ ID No 2; or
- c) the amino acid sequence of a fragment, of at least 5 amino acids, of a sequence as defined in a) or b).
9. The use as claimed in one of claims 1 to 8, characterized in that said biologically active substance is chosen from peptides, lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids and chemical substances.
10. The use as claimed in claim 9, characterized in that said biologically active substance is coupled by covalent attachment with said OmpA protein, or a fragment thereof.
11. The use as claimed in claim 10, characterized in that the coupling by covalent attachment is chemical coupling.
12. The use as claimed in claim 11, characterized in that one or more attachment elements is (are) introduced into said OmpA protein, or a fragment thereof, and/or into said biologically active substance, in order to facilitate the chemical coupling.
13. The use as claimed in claim 12, characterized in that said attachment element introduced is an amino acid.
14. The use as claimed in claim 10, characterized in that said biologically active substance coupled by covalent attachment with said OmpA protein, or a fragment thereof, is a recombinant chimeric protein resulting from the expression of a nucleic acid construct encoding said biologically active substance and said OmpA protein, or a fragment thereof.
15. The use as claimed in one of claims 10 to 14, characterized in that said biologically active substance is an antigen or a hapten.

16. The use as claimed in one of claims 1 to 15, for modifying the immune response against an antigen or a hapten.

17. The use as claimed in claim 16, for improving  
5 the immune response against an antigen or a hapten.

18. The use as claimed in one of claims 1 to 17, for preparing a pharmaceutical composition intended to prevent or to treat a disease with an active substance the effectiveness of which is modified by and/or linked  
10 to the internalization thereof by antigen-presenting cells.

19. The use as claimed in claim 18, for preparing a pharmaceutical composition intended to prevent or to treat a disease with an active substance, the effectiveness of which is modified by and/or linked to the internalization thereof by dendritic cells.  
15

20. The use as claimed in either of claims 18 and 19, for preparing a pharmaceutical composition intended to prevent or to treat cancers, preferably cancers associated with a tumor antigen, autoimmune diseases, allergies, graft rejections, cardiovascular diseases, diseases of the central nervous system, inflammatory diseases, infectious diseases or diseases linked to an immunodeficiency.  
20

21. The use as claimed in claim 20, for preparing a pharmaceutical vaccine composition intended to prevent or to treat an infectious disease or a cancer associated with a tumor antigen.  
25

22. The use as claimed in one of claims 18 to 21, characterized in that said pharmaceutical composition also comprises an adjuvant of immunity.  
30

23. The use as claimed in one of claims 18 to 22, characterized in that said pharmaceutical composition is vehicled in a form which makes it possible to improve the stability and/or immunogenicity thereof.  
35

24. The use as claimed in claim 23, characterized in that said pharmaceutical composition is vehicled in the form of a liposome, of a viral vector or of a

25-09-2000

FR 009902734

- 24 -

transformed host cell capable of expressing a  
recombinant chimeric protein resulting from the  
expression of a nucleic acid construct encoding said  
biologically active substance and said OmpA protein, or  
5 a fragment thereof.





## DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITE DE COOPERATION EN MATIÈRE DE BREVETS (PCT)

(51) Classification internationale des brevets <sup>7</sup> : <b>A61K 39/385, 39/39, A61P 31/00, 35/00, 37/00</b>	<b>A1</b>	(11) Numéro de publication internationale: <b>WO 00/27432</b>	(43) Date de publication internationale: 18 mai 2000 (18.05.00)
--	-----------	---	---

(21) Numéro de la demande internationale: PCT/FR99/02734

(22) Date de dépôt international: 8 novembre 1999 (08.11.99)

(30) Données relatives à la priorité:  
98/14007 6 novembre 1998 (06.11.98) FR

(71) Déposant (pour tous les Etats désignés sauf US): PIERRE FABRE MEDICAMENT [FR/FR]; 45, place Abel Gance, F-92100 Boulogne-Billancourt (FR).

(72) Inventeurs; et

(75) Inventeurs/Déposants (US seulement): BONNEFOY, Jean-Yves [FR/FR]; Les Noyers, F-74350 Le Sappey (FR). LECOANET, Sybille [CH/CH]; 41, A1 Résidence du Golf, CH-1196 Gland (CH). AUBRY, Jean-Pierre [FR/FR]; 60, chemin des Crêts des Crêts, F-74350 Cuvat (FR). JEANNIN, Pascale [FR/FR]; 135, chemin de Révule, F-01220 Divonne-les-Bains (FR). BAUSSANT, Thierry [FR/FR]; 35, rue Jean Jaurès, F-01200 Bellegarde (FR).

(74) Mandataires: MARTIN, Jean-Jacques etc.; Cabinet Regimbeau, 26, avenue Kléber, F-75116 Paris (FR).

(81) Etats désignés: AU, BR, CA, CN, JP, MX, US, ZA, brevet européen (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

## Publiée

*Avec rapport de recherche internationale.**Avant l'expiration du délai prévu pour la modification des revendications, sera republiée si des modifications sont reçues.*

(54) Title: USE OF AN ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS

(54) Titre: UTILISATION D'UNE PROTEINE OmpA D'ENTEROBACTERIE, POUR LE CIBLAGE SPECIFIQUE VERS LES CELLULES PRESENTATRICES D'ANTIGENES

## (57) Abstract

The invention concerns the use of an enterobacterium protein OmpA, preferably *Klebsiella pneumoniae* P40 protein, for specific targeting of a biologically active substance associated therewith towards antigen-presenting cells, in particular human dendritic cells. The invention also concerns the use of the OmpA protein for preparing a pharmaceutical composition for preventing and/or treating diseases, in particular cancers related to a tumour-associated antigen, autoimmune diseases or infectious diseases.

## (57) Abrégé

L'invention concerne l'utilisation d'une protéine OmpA d'entérobactérie, de préférence la protéine P40 *klebsiella pneumoniae*, pour le ciblage spécifique d'une substance biologiquement active qui lui est associée vers les cellules présentatrices d'antigènes, notamment les cellules dendritiques humaines. L'invention a également pour objet l'utilisation de la protéine OmpA pour la préparation d'une composition pharmaceutique destinée à la prévention et/ou le traitement de maladies, notamment les cancers associés à un antigène tumoral, les maladies auto-immunes ou les maladies infectieuses.




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5A




FIGURE 5B

WO 00/27432

1

PCT/FR99/02734

## SEQUENCE LISTING

&lt;110&gt; PIERRE FABRE MÉDICAMENT

<120> USE OF AN ENTEROBACTERIUM OmpA PROTEIN FOR  
SPECIFIC TARGETING OF A BIOLOGICALLY ACTIVE  
SUBSTANCE WHICH IS ASSOCIATED WITH IT TO  
ANTIGEN-PRESENTING CELLS

&lt;130&gt; D17777

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; FR 98 14007

&lt;151&gt; 1998-11-06

&lt;160&gt; 2

&lt;170&gt; PatentIn Ver. 2.2

&lt;210&gt; 1

&lt;211&gt; 1035

&lt;212&gt; ADN

&lt;213&gt; Klebsiella pneumoniae

&lt;220&gt;

&lt;221&gt; exon

&lt;222&gt; (1)..(1032)

&lt;220&gt;

&lt;221&gt; intron

&lt;222&gt; (1033)..(1035)

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1032)

&lt;400&gt; 1

atg	aaa	gca	att	ttc	gta	ctg	aat	gcg	gct	ccg	aaa	gat	aac	acc	tgg	48
Met	Lys	Ala	Ile	Phe	Val	Leu	Asn	Ala	Ala	Pro	Lys	Asp	Asn	Thr	Trp	
1				5				10						15		

tat	gca	ggt	ggt	aaa	ctg	ggt	tgg	tcc	cag	tat	cac	gac	acc	ggt	ttc	96
Tyr	Ala	Gly	Gly	Lys	Leu	Gly	Trp	Ser	Gln	Tyr	His	Asp	Thr	Gly	Phe	
		20					25						30			

tac	ggt	aac	ggt	ttc	cag	aac	aac	aac	ggt	ccg	acc	cgt	aac	gat	cag	144
Tyr	Gly	Asn	Gly	Phe	Gln	Asn	Asn	Asn	Gly	Pro	Thr	Arg	Asn	Asp	Gln	
		35				40						45				

ctt	ggt	gct	ggt	gcg	ttc	ggt	ggt	tac	cag	gtt	aac	ccg	tac	ctc	ggt	192
Leu	Gly	Ala	Gly	Ala	Phe	Gly	Gly	Tyr	Gln	Val	Asn	Pro	Tyr	Leu	Gly	
	50					55				60						

ttc	gaa	atg	ggt	tat	gac	tgg	ctg	ggc	cgt	atg	gca	tat	aaa	ggc	agc	240
Phe	Glu	Met	Gly	Tyr	Asp	Trp	Leu	Gly	Arg	Met	Ala	Tyr	Lys	Gly	Ser	
65					70				75					80		

gtt	gac	aac	ggt	gct	ttc	aaa	gct	cag	ggc	gtt	cag	ctg	acc	gct	aaa	288
Val	Asp	Asn	Gly	Ala	Phe	Lys	Ala	Gln	Gly	Val	Gln	Leu	Thr	Ala	Lys	

85								90				95					
ctg ggt tac ccg atc act gac gat	ctg gac atc tac acc cgt ctg ggc	336															
Leu Gly Tyr Pro Ile Thr Asp Asp	Leu Asp Ile Tyr Thr Arg Leu Gly																
100	105	110															
ggc atg gtt tgg cgc gct gac tcc aaa ggc aac tac gct tct acc ggc	384																
Gly Met Val Trp Arg Ala Asp Ser Lys Gly Asn Tyr Ala Ser Thr Gly																	
115	120	125															
gtt tcc cgt agc gaa cac gac act ggc gtt tcc cca gta ttt gct ggc	432																
Val Ser Arg Ser Glu His Asp Thr Gly Val Ser Pro Val Phe Ala Gly																	
130	135	140															
ggc gta gag tgg gct gtt act cgt gac atc gct acc cgt ctg gaa tac	480																
Gly Val Glu Trp Ala Val Thr Arg Asp Ile Ala Thr Arg Leu Glu Tyr																	
145	150	155															
cag tgg gtt aac aac atc ggc gac gcg ggc act gtg ggt acc cgt cct	528																
Gln Trp Val Asn Asn Ile Gly Asp Ala Gly Thr Val Gly Thr Arg Pro																	
165	170	175															
gat aac ggc atg ctg agc ctg ggc gtt tcc tac cgc ttc ggt cag gaa	576																
Asp Asn Gly Met Leu Ser Leu Gly Val Ser Tyr Arg Phe Gly Gln Glu																	
180	185	190															
gat gct gca ccg gtt gtt gct ccg gct ccg gct ccg gct ccg gaa gtg	624																
Asp Ala Ala Pro Val Val Ala Pro Ala Pro Ala Pro Ala Pro Glu Val																	
195	200	205															
gct acc aag cac ttc acc ctg aag tct gac gtt ctg ttc aac ttc aac	672																
Ala Thr Lys His Phe Thr Leu Lys Ser Asp Val Leu Phe Asn Phe Asn																	
210	215	220															
aaa gct acc ctg aaa ccg gaa ggt cag cag gct ctg gat cag ctg tac	720																
Lys Ala Thr Leu Lys Pro Glu Gly Gln Gln Ala Leu Asp Gln Leu Tyr																	
225	230	235															
act cag ctg agc aac atg gat ccg aaa gac ggt tcc gct gtt gtt ctg	768																
Thr Gln Leu Ser Asn Met Asp Pro Lys Asp Gly Ser Ala Val Val Leu																	
245	250	255															
ggc tac acc gac cgc atc ggt tcc gaa gct tac aac cag cag ctg tct	816																
Gly Tyr Thr Asp Arg Ile Gly Ser Glu Ala Tyr Asn Gln Gln Leu Ser																	
260	265	270															
gag aaa cgt gct cag tcc gtt gtt gac tac ctg gtt gct aaa ggc atc	864																
Glu Lys Arg Ala Gln Ser Val Val Asp Tyr Leu Val Ala Lys Gly Ile																	
275	280	285															
ccg gct ggc aaa atc tcc gct cgc ggc atg ggt gaa tcc aac ccg gtt	912																
Pro Ala Gly Lys Ile Ser Ala Arg Gly Met Gly Glu Ser Asn Pro Val																	
290	295	300															
act ggc aac acc tgt gac aac gtg aaa gct cgc gct gcc ctg atc gat	960																
Thr Gly Asn Thr Cys Asp Asn Val Lys Ala Arg Ala Ala Leu Ile Asp																	
305	310	315															
tgc ctg gct ccg gat cgt cgt gta gag atc gaa gtt aaa ggc tac aaa	1008																
Cys Leu Ala Pro Asp Arg Arg Val Glu Ile Glu Val Lys Gly Tyr Lys																	
325	330	335															

gaa gtt gta act cag ccg gcg ggt taa  
 Glu Val Val Thr Gln Pro Ala Gly  
 340

1035

&lt;210&gt; 2

&lt;211&gt; 344

&lt;212&gt; PRT

&lt;213&gt; Klebsiella pneumoniae

&lt;400&gt; 2

Met Lys Ala Ile Phe Val Leu Asn Ala Ala Pro Lys Asp Asn Thr Trp  
 1 5 10 15

Tyr Ala Gly Gly Lys Leu Gly Trp Ser Gln Tyr His Asp Thr Gly Phe  
 20 25 30

Tyr Gly Asn Gly Phe Gln Asn Asn Asn Gly Pro Thr Arg Asn Asp Gln  
 35 40 45

Leu Gly Ala Gly Ala Phe Gly Gly Tyr Gln Val Asn Pro Tyr Leu Gly  
 50 55 60

Phe Glu Met Gly Tyr Asp Trp Leu Gly Arg Met Ala Tyr Lys Gly Ser  
 65 70 75 80

Val Asp Asn Gly Ala Phe Lys Ala Gln Gly Val Gln Leu Thr Ala Lys  
 85 90 95

Leu Gly Tyr Pro Ile Thr Asp Asp Leu Asp Ile Tyr Thr Arg Leu Gly  
 100 105 110

Gly Met Val Trp Arg Ala Asp Ser Lys Gly Asn Tyr Ala Ser Thr Gly  
 115 120 125

Val Ser Arg Ser Glu His Asp Thr Gly Val Ser Pro Val Phe Ala Gly  
 130 135 140

Gly Val Glu Trp Ala Val Thr Arg Asp Ile Ala Thr Arg Leu Glu Tyr  
 145 150 155 160

Gln Trp Val Asn Asn Ile Gly Asp Ala Gly Thr Val Gly Thr Arg Pro  
 165 170 175

Asp Asn Gly Met Leu Ser Leu Gly Val Ser Tyr Arg Phe Gly Gln Glu  
 180 185 190

Asp Ala Ala Pro Val Val Ala Pro Ala Pro Ala Pro Ala Pro Glu Val  
 195 200 205

Ala Thr Lys His Phe Thr Leu Lys Ser Asp Val Leu Phe Asn Phe Asn  
 210 215 220

Lys Ala Thr Leu Lys Pro Glu Gly Gln Gln Ala Leu Asp Gln Leu Tyr  
 225 230 235 240

Thr Gln Leu Ser Asn Met Asp Pro Lys Asp Gly Ser Ala Val Val Leu  
 245 250 255

Gly Tyr Thr Asp Arg Ile Gly Ser Glu Ala Tyr Asn Gln Gln Leu Ser



260					265					270					
Glu	Lys	Arg	Ala	Gln	Ser	Val	Val	Asp	Tyr	Leu	Val	Ala	Lys	Gly	Ile
	275						280					285			
Pro	Ala	Gly	Lys	Ile	Ser	Ala	Arg	Gly	Met	Gly	Glu	Ser	Asn	Pro	Val
	290						295				300				
Thr	Gly	Asn	Thr	Cys	Asp	Asn	Val	Lys	Ala	Arg	Ala	Ala	Leu	Ile	Asp
305					310					315					320
Cys	Leu	Ala	Pro	Asp	Arg	Arg	Val	Glu	Ile	Glu	Val	Lys	Gly	Tyr	Lys
				325					330					335	
Glu	Val	Val	Thr	Gln	Pro	Ala	Gly								
			340												

T01E20" T90T E204


 PF86PCTSEQ  
 ATTY DK No. \_\_\_\_\_

# Declaration and Power of Attorney For Patent Application

## English Language Déclaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled. **USE OF AN ENTEROBACTERIUM OmpA PROTEIN FOR SPECIFIC TARGETING TO ANTIGEN-PRESENTING CELLS**

the specification of which (check one of the following)

☐ is attached hereto; ☐ was filed on \_\_\_\_\_ as Application Serial

No. \_\_\_\_\_ and was amended on \_\_\_\_\_; (if applicable)

☒ was filed as PCT International Application No. **PCT/FR99/02734**

on **08 NOVEMBER 1999** and was amended under PCT Article 19 on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
<u>98 14007</u> (Number)	<u>FRANCE</u> (Country)	<u>06/11/98</u> (Day/Month/Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

PCT/FR99/02734

08 NOVEMBER 1999

pending

(Application Serial No.)

(Filing Date)

(Status)  
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)  
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

G. Patrick Sage Reg. No. 37,710

Send Correspondence to:

G. Patrick Sage

THE FIRM OF HUESCHEN AND SAGE

500 Columbia Plaza

350 East Michigan Avenue

Kalamazoo, Michigan 49007-3856

United States of America

Direct Telephone Calls to: (name and telephone number) 616-382-0030

FULL NAME OF SOLE OR FIRST INVENTOR

BONNEFOY Jean-Yves

INVENTOR'S SIGNATURE

DATE  
May 9, 2001

RESIDENCE

LE SAPPEY - FRANCE *FRX*

CITIZENSHIP  
FRANCE

POST OFFICE ADDRESS

Les Noyers - 74350 LE SAPPEY - FRANCE

FULL NAME OF SECOND JOINT INVENTOR, IF ANY

LECOANET Sybille

INVENTOR'S SIGNATURE

DATE  
May 9, 2001

RESIDENCE

GLAND - SWITZERLAND *CHX*

CITIZENSHIP  
SWITZERLAND

POST OFFICE ADDRESS

41, Al Résidence du Golf - 1196 GLAND - SWITZERLAND

FULL NAME OF THIRD JOINT INVENTOR, IF ANY

AUBRY Jean-Pierre

INVENTOR'S SIGNATURE

DATE  
May 9, 2001

RESIDENCE

CUVAT - FRANCE *FRX*



CITIZENSHIP  
FRANCE

POST OFFICE ADDRESS

60 Chemin des Crêts des Crêts - 74350 CUVAT - FRANCE

400  
500  
TB

TELEPHONE

Full Name of Fourth Joint Inventor, if any <b>JEANNIN Pascale</b>		Inventor's Signature 	Date May 9, 2001
Residence <b>DIVONNE-LES-BAINS - FRANCE</b> <i>FRX</i>		Citizenship <b>FRANCE</b>	
Post Office Address <b>135 Chemin de Révule - 01220 DIVONNE-LES-BAINS - FRANCE</b>			
Full Name of Fifth Joint Inventor, if any <b>BAUSSANT Thierry</b>		Inventor's Signature 	Date May 9, 2001
Residence <u>new address:</u> <b>4 rue Alphonse Baudin, 01200 BELLEGARDE,</b> <b>BELLEGARDE - FRANCE</b> <i>FRX</i>		Citizenship <b>FRANCE</b>	
Post Office Address <u>new address:</u> <b>4 rue Alphonse Baudin, 01200 BELLEGARDE, FRANCE</b> <del>35 Rue Jean Jaurès - 01200 BELLEGARDE - FRANCE</del>			
Full Name of Sixth Joint Inventor, if any		Inventor's Signature	Date
Residence		Citizenship	
Post Office Address			